BioMarin (Phase III PARP) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

BioMarin (Phase III PARP) General Information

Description

Provider of drugs for the treatment of breast cancer. The company specializes in orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Medivation
Primary Office
  • 770 Lindaro Street
  • San Rafael, CA 94901
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioMarin (Phase III PARP) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioMarin (Phase III PARP)‘s full profile, request access.

Request a free trial

BioMarin (Phase III PARP) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioMarin (Phase III PARP)‘s full profile, request access.

Request a free trial